News | May 17, 2022
Eight Roads announce US $ 250 million healthcare fund for India
This new fund is amongst the largest for the sector in India
This new fund is amongst the largest for the sector in India
Multiples is the first private equity (PE) investor in the company
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
In clinical trials, treatment proved more effective than other therapies evaluated
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Subscribe To Our Newsletter & Stay Updated
